Dr Rotow on the Investigation of ABBV-637 Plus Osimertinib in EGFR-Mutated NSCLC
October 27th 2023
Julia Rotow, MD, discusses results from a first-in-human phase 1 study of the EGFR-targeting, BCL-XL–inhibiting antibody-drug conjugate ABBV-637 in combination with osimertinib in patients with relapsed/refractory, EGFR-mutated non–small cell lung cancer.